Top Page
EKF Diagnostics Holdings
(LSE:EKF)
EKF Diagnostics Holdings (EKF) vs. iShares MSCI United Kingdom ETF (EWC)
EKF Diagnostics Holdings Business Overview & Revenue Model
EKF Diagnostics Holdings Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.19M | 52.61M | 66.64M | 81.84M | 65.26M |
| Gross Profit | 21.48M | 23.86M | 24.04M | 39.37M | 37.42M |
| EBITDA | 11.16M | 7.68M | -2.18M | 27.39M | 20.04M |
| Net Income | 6.24M | 2.35M | -9.58M | 15.85M | 11.11M |
Balance Sheet | |||||
| Total Assets | 81.75M | 80.85M | 89.29M | 115.12M | 101.27M |
| Cash, Cash Equivalents and Short-Term Investments | 13.01M | 6.02M | 11.58M | 20.34M | 21.91M |
| Total Debt | 1.32M | 4.10M | 1.55M | 2.63M | 1.58M |
| Total Liabilities | 8.53M | 12.63M | 14.77M | 20.38M | 23.07M |
| Stockholders Equity | 72.33M | 67.12M | 73.35M | 94.12M | 77.65M |
Cash Flow | |||||
| Free Cash Flow | 11.41M | -664.00K | 3.86M | 4.59M | 11.16M |
| Operating Cash Flow | 13.66M | 6.31M | 9.69M | 10.24M | 13.81M |
| Investing Cash Flow | -2.66M | -5.64M | -8.93M | -5.48M | 1.34M |
| Financing Cash Flow | -4.08M | -3.65M | -11.04M | -6.16M | -5.21M |
EKF Diagnostics Holdings Technical Analysis
EKF Diagnostics Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £120.36M | 19.42 | 8.95% | 4.80% | -4.59% | 165.38% | |
65 Neutral | €6.48B | 19.09 | -1.30% | 2.17% | -0.15% | -41.88% | |
55 Neutral | £7.29M | 1,175.00 | 0.08% | ― | 56.29% | ― | |
52 Neutral | £57.75M | ― | -38.49% | ― | ― | ― | |
45 Neutral | £20.17M | ― | -65.64% | ― | 1.65% | -102.83% | |
40 Underperform | £42.38M | ― | -63.28% | ― | 1557.07% | 24.70% | |
| ― | £66.92M | 8.51 | 31.81% | ― | ― | ― |
EKF Diagnostics Holdings Corporate Events
EKF Diagnostics Holdings plc has completed the cancellation of 5,836,774 ordinary shares, including those previously held in treasury, as part of its share buyback program. This action reduces the company’s total issued share capital to 449,093,790 ordinary shares, which will now serve as the basis for shareholder voting rights calculations. The company continues to pursue additional share buybacks up to approximately £1.0 million, reflecting its strategic focus on optimizing capital structure and enhancing shareholder value.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings PLC has announced a significant change in its shareholding structure, with Schroders PLC increasing its stake in the company. This acquisition of shares by Schroders PLC, a major investment firm based in London, raises its total shareholding to over 6%, indicating a vote of confidence in EKF Diagnostics’ market position and future prospects. This development is likely to impact EKF’s market dynamics and could influence investor perceptions positively.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced its total issued share capital, consisting of 454,930,564 Ordinary Shares, with 5,836,774 held in treasury, resulting in 449,093,790 shares carrying voting rights. This figure is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure and Transparency Rules, impacting how they manage their investments and compliance obligations.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced an additional share buyback program following the successful completion of an initial program. The company plans to repurchase up to £1.0 million worth of ordinary shares, which will be held in treasury. This move is facilitated by Harwood Capital Management, ensuring that the aggregate indirect beneficial interest of Christopher Mills, a non-executive director, remains stable. The buyback is structured to avoid triggering a mandatory offer under the City Code on Takeovers and Mergers, thus maintaining the current shareholder structure.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced that all resolutions were passed at its recent Annual General Meeting, indicating strong shareholder support. This outcome reflects positively on the company’s governance and strategic direction, potentially reinforcing its market position and stakeholder confidence.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc announced positive trading results for the first quarter of 2025, aligning with management expectations. The company has benefited from a streamlined business model focusing on higher-margin products, particularly in Hematology, and has a strong order book for analyzers in Latin America. The Life Sciences division continues to perform well, with robust sales of β-HB and an improved pipeline for contract manufacturing. Cash generation remains strong, supporting growth investments and a successful £1m share buyback program, with expectations for cash levels to exceed those of FY 2024.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has successfully completed its share buyback program, purchasing a total of 4,636,774 ordinary shares at an average price of 21.48 pence per share, with the final transaction involving 367,000 shares. This buyback is part of a strategic financial maneuver to manage the company’s capital structure and enhance shareholder value. The completion of this program also involved transactions with Harwood, acting as an investment manager for Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensuring that Mr. Mills’ aggregate indirect beneficial interest remains stable. The buyback reduces the number of shares in circulation, potentially increasing the value of remaining shares and impacting shareholder voting rights.
The most recent analyst rating on (GB:EKF) stock is a Buy with a £0.29 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
EKF Diagnostics Holdings plc has announced the buyback of 992,762 of its ordinary shares at a weighted average price of 21.5 pence per share, which will be held in treasury. This move is part of a strategic effort to manage the company’s share capital and maintain the indirect beneficial interest of Mr. Mills, a significant stakeholder, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. The buyback may impact the company’s market positioning by potentially increasing shareholder value and demonstrating confidence in its financial stability.
EKF Diagnostics Holdings plc has announced a share buyback, purchasing 709,125 of its ordinary shares at an average price of 21.3519 pence per share, which will be held in treasury. This transaction, which includes a significant purchase from Harwood as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, ensures that Mr. Mills’ indirect beneficial interest remains stable, not exceeding 30% of the total voting rights. This strategic move may impact the company’s market positioning by potentially increasing shareholder value and maintaining control over voting rights.
EKF Diagnostics Holdings plc announced the buyback of 177,279 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This transaction is part of a strategic move to manage its share capital and maintain the aggregate indirect beneficial interest of Mr. Mills, a significant shareholder, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This buyback could impact the company’s shareholding structure and influence shareholder decisions regarding their interests in the company.
EKF Diagnostics Holdings plc has announced the purchase of 200,000 of its ordinary shares at a price of 21 pence per share, which will be held in treasury. This share buyback is part of the company’s strategy to manage its capital structure and maintain the aggregate indirect beneficial interest of Mr. Mills, a non-executive director, at approximately the same level, ensuring it does not exceed 30% of the total voting rights. This move may impact the company’s market positioning by potentially increasing shareholder value and stabilizing its share price.
EKF Diagnostics Holdings plc announced a share buyback, purchasing 200,000 ordinary shares at 21 pence each, which will be held in treasury. This move is part of a strategic effort to manage the company’s capital structure and maintain the aggregate indirect beneficial interest of Mr. Mills, a significant stakeholder, at a stable level. The buyback reflects EKF’s commitment to optimizing shareholder value and may impact the company’s market positioning by potentially increasing share value and demonstrating financial stability.
EKF Diagnostics Holdings plc has published its Annual Report and Accounts for the year ending December 31, 2024, along with the notice for its 2025 Annual General Meeting (AGM). The AGM is scheduled for May 20, 2025, in London, with provisions for shareholders to participate online or via phone. The company encourages shareholders to vote online and submit questions in advance, streamlining the process for engagement and decision-making.